Welcome to our dedicated page for Io Biotech news (Ticker: IOBT), a resource for investors and traders seeking the latest updates and insights on Io Biotech stock.
IO Biotech Inc. (IOBT) is a clinical-stage biopharmaceutical leader developing T-win platform-based cancer immunotherapies. This dedicated news hub provides investors and researchers with verified updates on clinical trial progress, regulatory milestones, and strategic partnerships.
Access real-time announcements about IO Biotech's innovative pipeline targeting immune inhibitory pathways, including IDO and PD-L1-focused therapies. Our curated collection features earnings reports, research publications, and corporate developments directly from company filings and authorized sources.
Key updates include phase trial results, FDA communications, intellectual property advancements, and executive team announcements. Bookmark this page for streamlined tracking of IO Biotech's progress in advancing novel cancer treatments through methodical clinical evaluation.
IO Biotech (IOBT) presented new preclinical data for two cancer vaccine candidates at the AACR Annual Meeting 2025 in Chicago. The company showcased findings for:
1. IO102-IO103: Their lead therapeutic vaccine targeting IDO1 and PD-L1 demonstrated strong T-cell responses and unique tumor microenvironment modulation in mouse models, with effects distinct from conventional PD-1/PD-L1 inhibitors.
2. IO170: Their TGF-β-directed vaccine showed significant tumor growth inhibition in breast and prostate cancer models, increasing CD8+ T-cell density and reducing suppressive cells like M2 macrophages.
Both vaccines, developed using IO Biotech's T-win® platform, showed promising results in reshaping the tumor microenvironment to enhance anti-tumor immunity.
IO Biotech (IOBT) announced the acceptance of two abstracts for presentation at the 2025 AACR Annual Meeting in Chicago. The presentations will showcase new non-clinical data for their cancer vaccine candidates:
1. Data demonstrating how IO102-IO103, their lead candidate currently in Phase 3 trials for advanced melanoma, controls tumor growth through target-specific T-cell activation.
2. Preclinical data for IO170, their pipeline candidate targeting TGF-beta, showing promising antitumor activity.
Additionally, Dr. Mads Hald Andersen, the company's scientific co-founder, will chair and speak at an educational session on cancer vaccines, exploring the latest advances in cancer vaccine research.
IO Biotech (Nasdaq: IOBT) has been recognized as the 9th most innovative company in biotechnology on Fast Company's World's Most Innovative Companies of 2025 list. The clinical-stage biopharmaceutical company earned this distinction for its innovative approach to immune-modulatory cancer vaccines.
The company's T-win® platform develops off-the-shelf therapeutic cancer vaccines designed to target and kill both tumor cells and immune-suppressive cells in the tumor microenvironment. Their lead candidate, Cylembio®, is currently in:
- A global Phase 3 trial for advanced melanoma with primary endpoint readout expected in Q3 2025
- Phase 2 trials combining with pembrolizumab for non-small cell lung cancer and head and neck cancer
- Phase 2 trials as neoadjuvant and adjuvant treatment for resectable melanoma and head and neck cancer
The recognition by Fast Company highlights IO Biotech's potential to transform the oncology treatment paradigm with products designed to be available at diagnosis.
IO Biotech (IOBT) reported key developments in Q4 2024 for its therapeutic cancer vaccine Cylembio®. The company's pivotal Phase 3 trial completed enrollment ahead of schedule with 407 patients, with primary endpoint readout expected in Q3 2025. A Biologics License Application (BLA) submission to FDA is planned by year-end 2025.
The company's Phase 2 basket trial for resectable melanoma and head and neck cancer completed enrollment with 95 patients, with initial data expected in H2 2025. The Phase 2 trial IOB-022/KN-D38 met its primary endpoint of overall response rate in head and neck cancer, with promising activity in lung cancer treatment.
Financial position shows $60.0 million in cash and equivalents at Q4 2024 end, supplemented by up to €57.5 million in EIB debt financing. The committed tranches are expected to extend cash runway into Q2 2026.
IO Biotech (IOBT) presented new preclinical data for its novel peptide vaccine IO170 at the AACR-IO conference. The vaccine targets Transforming Growth Factor Beta (TGF-β), a key immune-suppressive factor in solid tumors. Unlike existing approaches that inhibit TGF-β systemically, IO170 selectively modulates TGF-β activity using IO Biotech's proprietary T-win® platform.
The preclinical studies demonstrated that IO170 significantly reduced tumor growth in pancreatic adenocarcinoma and prostate cancer models. The vaccine induced robust immune responses and reshaped the tumor microenvironment (TME) without causing systemic toxicity or adverse off-target effects. The company is preparing for an Investigational New Drug Application (IND) submission to FDA for IO170.
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company focused on developing immune-modulatory, off-the-shelf therapeutic cancer vaccines, has announced its participation in the 45th Annual Cowen Health Care Conference. The company's presentation will feature updates on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted).
The presentation will be delivered by Mai-Britt Zocca, PhD, President and CEO, on Wednesday, March 5, 2025, from 2:30-3:00 PM EST in Boston, MA. The company's leadership team, including CFO Amy Sullivan and CMO Qasim Ahmad, MD, will be available for one-on-one investor meetings during the conference. A webcast replay will be accessible on the company's website for 90 days following the presentation.
IO Biotech (IOBT) announced the publication of preclinical study results for IO112, their second immune-modulatory therapeutic cancer vaccine candidate targeting arginase 1 (Arg1), in the Journal for ImmunoTherapy of Cancer. The study demonstrated that IO112 treatment inhibits tumor growth through changes in the tumor microenvironment (TME), showing how Arg1-specific T cells expanded by the vaccine enhance anti-tumor immunity by reprogramming tumor-associated macrophages (TAMs).
The research revealed that IO112 treatment directly impacts TAMs, completely changing their phenotype. This is particularly significant as Arg1-expressing TAMs are a major obstacle in cancer immunotherapy due to their role in creating an immunosuppressive TME. The company plans to submit an Investigational New Drug Application (IND) to the US FDA in 2025.
IO Biotech (IOBT) has completed enrollment ahead of schedule for its Phase 2 basket trial studying IO102-IO103, its lead therapeutic cancer vaccine candidate, in combination with Merck's KEYTRUDA®. The trial focuses on treating resectable melanoma or squamous cell carcinoma of the head and neck (SCCHN) before and after surgery.
The multicenter trial has enrolled 93 patients across sites in the United States, Europe, and Australia. The study's primary endpoint is major pathologic response (MPR), measuring the reduction in viable tumor cells after treatment. Secondary endpoints include pathological complete response, ORR, disease-free survival, event-free survival, and safety.
Initial data from this Phase 2 trial is expected in 2025, coinciding with anticipated results from the company's Phase 3 trial in advanced melanoma patients in the first half of 2025. The vaccine is designed as an off-the-shelf option and has shown encouraging clinical activity without significant systemic toxicity across three first-line advanced cancer indications.
IO Biotech (IOBT) has secured a loan facility of up to €57.5 million from the European Investment Bank (EIB) to advance its therapeutic cancer vaccines development. The facility includes three committed tranches totaling €37.5 million and an uncommitted accordion tranche of €20 million. The first two tranches are expected to be available in Q1 2025.
The unsecured loan has no minimum cash covenants and will extend the company's cash runway into Q2 2026. The facility includes warrants issuance to EIB for each tranche, with 6-year maturity terms and deferred payments. Tranche C requires raising an additional $50 million and submitting a marketing authorization application for IO102-IO103 in the U.S. or EU.
IO Biotech (IOBT) reported Q3 2024 financial results and business updates. The company's pivotal Phase 3 trial of IO102-IO103 cancer vaccine in combination with KEYTRUDA® for advanced melanoma is on track, with primary endpoint data expected in H1 2025. The company reported a net loss of $24.0 million for Q3 2024, compared to $21.7 million in Q3 2023. R&D expenses increased to $20.2 million, up from $17.7 million year-over-year. Cash position stands at $80.2 million, expected to support operations into Q4 2025.
